Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOGNASDAQ:ARVNNASDAQ:CGEMNASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.86-0.7%$5.35$3.75▼$8.61$109.90M2.4880,884 shs49,229 shsARVNArvinas$6.07-3.5%$7.95$5.94▼$37.38$443.06M2.211.31 million shs2.61 million shsCGEMCullinan Therapeutics$7.13-6.4%$8.05$6.85▼$28.11$420.78M-0.07589,549 shs427,179 shsTSHATaysha Gene Therapies$2.37+1.3%$1.68$1.05▼$4.32$485.98M0.92.83 million shs2.93 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-0.72%-8.41%+42.03%+19.93%+685,999,900.00%ARVNArvinas-3.50%-8.52%-17.97%-65.65%-80.64%CGEMCullinan Therapeutics-6.43%-7.23%-7.88%-25.65%-72.97%TSHATaysha Gene Therapies+1.28%+24.41%+85.16%+46.30%-7.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition2.2258 of 5 stars3.50.00.00.03.91.70.0ARVNArvinas3.522 of 5 stars4.33.00.00.01.82.51.3CGEMCullinan Therapeutics2.362 of 5 stars3.52.00.00.02.12.50.6TSHATaysha Gene Therapies2.1097 of 5 stars3.50.00.00.02.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00191.55% UpsideARVNArvinas 2.58Moderate Buy$20.91244.51% UpsideCGEMCullinan Therapeutics 3.00Buy$32.00348.81% UpsideTSHATaysha Gene Therapies 3.00Buy$6.43171.25% UpsideCurrent Analyst Ratings BreakdownLatest ACOG, ARVN, TSHA, and CGEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.005/2/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.005/2/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $8.005/2/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $16.005/2/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$24.00 ➝ $14.005/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$81.00 ➝ $24.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A($1.08) per shareN/AARVNArvinas$426.90M1.04N/AN/A$8.17 per share0.74CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.61 per shareN/ATSHATaysha Gene Therapies$8.33M58.32N/AN/A$0.40 per share5.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$13.77M-$1.82N/A∞N/AN/AN/A-344.17%5/15/2025 (Estimated)ARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)CGEMCullinan Therapeutics-$153.16M-$2.91N/AN/AN/AN/A-26.54%-25.32%N/ATSHATaysha Gene Therapies-$111.57M-$0.363.76N/AN/A-229.67%-106.36%-49.16%5/15/2025 (Estimated)Latest ACOG, ARVN, TSHA, and CGEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CGEMCullinan Therapeutics-$0.80N/AN/AN/AN/AN/A5/15/2025Q1 2025ACOGAlpha Cognition-$0.58N/AN/AN/AN/AN/A5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08N/AN/AN/A$1.48 millionN/A5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/31/2025Q4 2024ACOGAlpha Cognition-$0.48-$0.51-$0.03-$0.51N/AN/A2/27/2025Q4 2024CGEMCullinan Therapeutics-$0.75-$0.73+$0.02-$0.73N/AN/A2/26/2025Q4 2024TSHATaysha Gene Therapies-$0.08-$0.07+$0.01-$0.07$2.05 million$2.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A1.501.50ARVNArvinasN/A4.644.64CGEMCullinan TherapeuticsN/A24.4624.46TSHATaysha Gene Therapies0.485.515.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AARVNArvinas95.19%CGEMCullinan Therapeutics86.31%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition31.52%ARVNArvinas4.73%CGEMCullinan Therapeutics7.16%TSHATaysha Gene Therapies2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million10.97 millionN/AARVNArvinas42072.99 million65.18 millionOptionableCGEMCullinan Therapeutics3059.02 million54.69 millionOptionableTSHATaysha Gene Therapies180205.06 million199.41 millionOptionableACOG, ARVN, TSHA, and CGEM HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Buys 496,482 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 13 at 6:54 AM | marketbeat.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on ThursdayMay 13 at 1:29 AM | americanbankingnews.comDAFNA Capital Management LLC Makes New $904,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 10, 2025 | marketbeat.comTaysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15May 8, 2025 | globenewswire.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comMarshall Wace LLP Lowers Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 8, 2025 | marketbeat.comWill Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should KnowMay 6, 2025 | zacks.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 9.3% - What's Next?May 5, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from BrokeragesMay 5, 2025 | americanbankingnews.comAcuta Capital Partners LLC Cuts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 4, 2025 | marketbeat.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 11.41%May 3, 2025 | aaii.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from AnalystsMay 2, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Makes New $8.65 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 1, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 30, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 30, 2025 | marketbeat.comRenaissance Technologies LLC Makes New $1.52 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 29, 2025 | marketbeat.comAvoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 23, 2025 | marketbeat.comB Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 23, 2025 | marketbeat.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 16.13%April 22, 2025 | aaii.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co.April 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACOG, ARVN, TSHA, and CGEM Company DescriptionsAlpha Cognition NASDAQ:ACOG$6.86 -0.05 (-0.72%) As of 05/14/2025 03:59 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Arvinas NASDAQ:ARVN$6.07 -0.22 (-3.50%) As of 05/14/2025 04:00 PM EasternArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Cullinan Therapeutics NASDAQ:CGEM$7.13 -0.49 (-6.43%) As of 05/14/2025 04:00 PM EasternCullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$2.37 +0.03 (+1.28%) As of 05/14/2025 04:00 PM EasternTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
